Presently, the available data are insufficient to assess whether the supplementation of HF diets with n-3 PUFA, carried either by PO or FO, can make any difference in the apoA-1 metabolic outcomes, with the aim of preventing or treating metabolic disorders. This evidence concerns the gene APOA1 and metabolic disease.